Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Background Sodium glucose cotransporter‐2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also remains uncertainty regarding the prognostic value of SBP variability for different clinical outcomes. Methods and Results Using individual partic...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Robert A. Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I. Chang, Hiddo J. L. Heerspink, Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L. Neuen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-07-01
coleção:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:	blood pressure variability canagliflozin clinical outcomes clinical trials SGLT2 inhibitors
Acesso em linha:	https://www.ahajournals.org/doi/10.1161/JAHA.122.028516
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!